| A-423,579 | |
|---|---|
|
4-(4-{3-[3-(Dimethylamino)pyrrolidin-1-yl]propoxy}-3,5-difluorophenyl)benzonitrile[citation needed] |
|
| Identifiers | |
| CAS number | 461045-17-0 |
| PubChem | 11349657 (R), 22994515 |
| ChemSpider | 9524593 (R) |
| ChEMBL | CHEMBL498228 |
| Jmol-3D images | Image 1 Image 2 |
|
|
|
|
| Properties | |
| Molecular formula | C22H25F2N3O |
| Molar mass | 385.45 g mol−1 |
| Exact mass | 385.196568847 g mol-1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.[1][2]
| This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)